RxDoctor Payments Data

Nelda Ordonez, MD

General Practice · Chula Vista, CANPI 1922410919

Payments from drug & device makers

$627in general payments, 2019–2025

Across 6 payments — averaging $104.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$134
  • Johnson & Johnson$130
  • Heartflow, Inc.$122
  • Boston Scientific$120
  • AstraZeneca$120

What the payments were for

  • Food & beverage$627100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott2$134
Johnson & Johnson1$130
Heartflow, Inc.1$122
Boston Scientific1$120
AstraZeneca1$120

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$627 in reported general payments places this provider in the 70th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$284,973
Medicare patients
400
Services billed
3,257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban276$83,452
JanuviaSitagliptin Phosphate146$42,795
JardianceEmpagliflozin94$28,329
Sevelamer Hcl18$24,367
Lupron DepotLeuprolide Acetate11$23,785
RetacritEpoetin Alfa-Epbx54$19,269
TradjentaLinagliptin72$18,482
TrulicityDulaglutide35$14,595
EpogenEpoetin Alfa27$12,947
ErtapenemErtapenem Sodium47$10,054
Combivent RespimatIpratropium/Albuterol Sulfate19$9,843
XareltoRivaroxaban22$9,573
InvokanaCanagliflozin24$8,645
EntrestoSacubitril/Valsartan26$8,607
Bumetanide106$8,174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto, Invokana$130$18,21946 claims
AstraZenecaBrilinta$120$7,66534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 12,963 general practice providers in California.

Other general practice in Chula Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →